Decreasing Expression of Cancer-Driving Genes
SY-1365 is a first-in-class potent and selective inhibitor of the cyclin-dependent kinase 7 (CDK7) that is in a Phase 1 clinical trial in patients with advanced solid tumors.
SY-1365 has shown significant anti-proliferative and pro-apoptotic activity in multiple preclinical models of difficult-to-treat solid tumors and blood cancers, including ovarian, breast and small cell lung cancers and acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). SY-1365 has induced anti-tumor activity in patient-derived xenograft models of ovarian cancer and breast cancer, including significant regressions at a twice weekly dosing regimen consistent with the initial regimen being used in the Phase 1 clinical trial. In preclinical studies, SY-1365 has also been shown to preferentially kill cancer cells over non-cancerous cells and can lower the expression of key cancer-driving genes.
Upon completing the dose escalation portion of the ongoing Phase 1 trial, we plan to expand the trial to focus initially on ovarian cancer.